What is Oncoustics?
Oncoustics operates at the intersection of deep learning and clinical diagnostics, providing a specialized suite of applications that enable rapid, cost-effective liver disease assessment. By utilizing existing ultrasound infrastructure, the company effectively lowers the barrier to entry for high-quality diagnostic monitoring, thereby reducing the reliance on invasive procedures and costly specialist referrals. Their technology is engineered to integrate seamlessly into existing clinical workflows, offering practitioners actionable insights that improve patient outcomes through early detection. The company's market position is bolstered by its commitment to rigorous clinical validation and strategic partnerships with international healthcare providers, ensuring that their AI-driven solutions meet the stringent requirements of modern medical environments.
How much funding has Oncoustics raised?
Oncoustics has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2022): $5M with participation from Creative Ventures and Saltagen Ventures
Key Investors in Oncoustics
Saltagen Ventures
Saltagen Ventures empowers early-stage deep biotechnology startups to grow their businesses globally, focusing on the North American and Asian markets. The company specializes in identifying and scaling high-growth potential bioscience technology firms with strong fundamental technology.
Creative Ventures
A venture capital firm focused on investing in companies that solve humanity's most pressing challenges through deep technology and scalable innovation.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Oncoustics?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the company's regulatory footprint and scaling its diagnostic platform across diverse international markets. As Oncoustics continues to refine its machine learning models, the focus will shift toward broadening the scope of its non-invasive surveillance capabilities beyond liver health. The company is expected to prioritize the integration of its software with a wider array of ultrasound devices, further cementing its role as a critical infrastructure provider in the digital health ecosystem. By maintaining a focus on clinical efficacy and streamlined diagnostic pathways, Oncoustics is well-positioned to capture significant market share in the rapidly evolving landscape of AI-enabled healthcare technology.
See full Oncoustics company page
